Straits Times Index
3,258.90 +1.72 (+0.05%) Nikkei
28,041.48 +258.55 (+0.93%) Hang Seng
20,400.11 +90.98 (+0.45%) FTSE 100
7,631.74 +11.31 (+0.15%) Bitcoin USD
28,408.67 +247.36 (+0.88%) CMC Crypto 200
621.79 +7.58 (+1.23%)
Graphite Bio, Inc. (GRPH)
After hours:
| Previous close | 2.4100 |
| Open | 2.4200 |
| Bid | 2.3800 x 1000 |
| Ask | 2.4600 x 1000 |
| Day's range | 2.3800 - 2.4800 |
| 52-week range | 1.5900 - 5.3100 |
| Volume | |
| Avg. volume | 289,685 |
| Market cap | 142.501M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.50 |
- Business Wire
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., March 20, 2023--Graphite Bio, Inc. (Nasdaq: GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results.
- Business Wire
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
SOUTH SAN FRANCISCO, Calif., February 22, 2023--Graphite Bio, Inc. (Nasdaq: GRPH) today announced that it has completed a review of its business, including the status of its programs, resources and capabilities. The company has decided to discontinue further development of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease and to initiate a process to explore a range of strategic alternatives.
- Zacks
Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround
Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
